Navigation Links
Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement
Date:11/25/2009

- Agreement Provides Financial Flexibility, Allowing Company to Access Capital at its Discretion -

LAVAL, Quebec, Nov. 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced it has entered into a standby equity distribution agreement (SEDA) with YA Global Master SPV Ltd., a fund managed by Yorkville Advisors, LLC. Under the terms of the agreement, YA has committed to provide up to $25 million of capital during the next three years, at Labopharm's discretion, through the purchase of newly issued Labopharm common shares. (All currency figures are in Canadian dollars.)

"With a number of potential cash-generating milestones on the horizon, a standby equity facility is well suited to our Company at this time," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Should we choose to access it, the facility provides a flexible, low cost source of capital in an amount and at the time of our choosing, with a built-in minimum price."

The Company can draw on YA's commitment by sending draw down notices from time to time. Each draw down notice is subject to a maximum amount of $2 million, as well as a minimum price, below which the Company will not issue shares to YA. Subject to the applicable minimum price, the common shares will be issued at a predetermined discount, up to a maximum of 5%, to the prevailing share price. Individual draw downs cannot exceed the number of shares that would represent more than 5% of the market capitalization of the Company or the number of shares that would cause YA and its affiliates to own more than 9.9% of the issued and outstanding shares of the Company. The maximum number of shares that the Company can issue under the agreement is limited to the lower of 11,426,533 common shares and 19.9% of the common shares issued and outstan
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Best Cheap Hosting USA is ... The site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ... people from around the world. , “iPower is one ... and is providing various kinds of useful products for ... on offering excellent customer service and a number of ...
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... The Childrens Report of Sleep Patterns (CRSP), a ... and sleep disturbances for school-aged children, may be a ... hygiene, and sleep disturbances in children eight to 12 ... will be presented on Wednesday at SLEEP 2008, the ...
... Among the Top Healthcare IT Providers Underscores Cognizant,s ... in the Healthcare and Life Sciences Industry, ... leading provider of global consulting, technology and business,process ... ranked the 11th,largest healthcare IT provider by Healthcare ...
... For the first time, UCLA researchers have discovered that ... regions that help store memory. Reported in the June ... emphasize the importance of early detection of the disorder, ... , Sleep apnea occurs when a blocked airway ...
... Team of Physicians Give Manuel ... Uribe A New Lease on Life, DANVERS, Mass., June 10 ... man in the world, has,lost more than one-third of his body weight and ... by Dr. Barry Sears,creator of the Zone Diet. As he approaches his 43rd ...
... XL Capital Ltd,(NYSE: XL ) (the "Company") ... judgment handed down by the U.S. District Court for ... Lynch International. Merrill Lynch,International filed a complaint against Security ... Assurance Inc. (XLCA), relating to,certain credit default swap transactions ...
... effects of biomarkers most promising way,to help older ... 10 The Kronos Longevity,Research Institute (KLRI) has ... "the vicious triad" of the aging process: oxidative ... age-related,deteriorations and diseases. Longevity scientists across the country ...
Cached Medicine News:Health News:'Children's Report of Sleep Patterns' a reliable, maybe a valid measure of children's sleep habits 2Health News:Cognizant Ranks #11 on Healthcare Informatics 100 List 2Health News:Cognizant Ranks #11 on Healthcare Informatics 100 List 3Health News:Memory loss linked to common sleep disorder 2Health News:Memory loss linked to common sleep disorder 3Health News:Video: World's Heaviest Man Celebrates Birthday and Weight Loss Milestone 2Health News:Video: World's Heaviest Man Celebrates Birthday and Weight Loss Milestone 3Health News:XL Capital Ltd Issues Statement Regarding Merrill Lynch Lawsuit Against XL Capital Assurance Inc. (XLCA) a Subsidiary of Security Capital Assurance Ltd 2Health News:New KLRI Reports Shows Longevity Science Moving Beyond Studying the Obvious to the 'Downward Spiral' Paradigm in the Aging Process 2Health News:New KLRI Reports Shows Longevity Science Moving Beyond Studying the Obvious to the 'Downward Spiral' Paradigm in the Aging Process 3
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... and AUSTIN, Texas , Oct. ... LLC today announced they have entered into a ... immunotherapies designed to target cancers. PhosImmune ... displayed on the surfaces of tumor cells in ... (PTTs), derived from proteins that play a role ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... Medical Hematology and Oncology CHU Lapeyronie, Montpellier ... that has long been recognized as a marker ... range of diagnostic markers to monitor infection and ... a necessity throughout the health care sector, it ...
... ,Since the first system was invented in 1957, ... patient care. During the 1960s, blood gas analysis ... considered "the most important laboratory test for critically ... Dr. John Severinghaus, inventor of the blood gas ...
Cached Medicine Technology:Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 2Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 3Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 4Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 2Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 3Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 4
... Dengue virus belongs to the Flavavirus group ... throughout the tropics.,Symptoms of Dengue fever are ... in the back and limbs, lymphadenopathy,maculopapular rash ... professional use as an aid in the ...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
For the rapid determination of human chorionic gonadotropin (hCG) in urine. The test strip is used to obtain a visual qualitative result....
Medicine Products: